Home > Publications database > Second Primary Lung Cancer Associated With Family History of Lung Cancer. > print

001     306672
005     20251202115946.0
024 7 _ |a 10.1002/cam4.71431
|2 doi
024 7 _ |a pmid:41317095
|2 pmid
024 7 _ |a pmc:PMC12664089
|2 pmc
037 _ _ |a DKFZ-2025-02665
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Zitricky, Frantisek
|0 0000-0001-7600-7143
|b 0
245 _ _ |a Second Primary Lung Cancer Associated With Family History of Lung Cancer.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1764600554_815119
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:C020# Z999
520 _ _ |a Familial clustering of initial primary lung cancer (IPLC) may be related to shared smoking habits, other environmental exposures and hereditary factors, but whether familial risk also influences the risk of second primary LC (SPLC) is not well known. We aimed to carry out a family study between first-degree relatives on SPLCs in Sweden.Population data on Swedish family relationships and the diagnosed cancers were obtained from the national registers from 1961 to 2021. IPLC was diagnosed in 54,429 patients of whom 534 were diagnosed with SPLC. Familial risk was assessed through the standardized incidence ratio (SIR with 95% confidence interval) adjusted for several potential confounders, including sex, age, calendar period, educational level and geographic region. Familial risks were analyzed by type of proband, histology and sex. In addition, we estimated the effect of family history on the cumulative proportion of patients developing SPLC by sex and histology.The estimated SIR for SPLC was 3.98 in patients without family history and 5.24 among those with a history of lung cancer in first-degree relatives. The SIR values depended on the histology of IPLC and of SPLC, with the highest SIRs for concordant histologies. For the adenocarcinoma-adenocarcinoma sequence, SIR estimates were 5.60 and 7.51 for non-familial and familial patients, respectively. The familial risks were further modulated by sex and type of affected relative, with the highest SIR for females with affected mothers (9.14).The results showed a positive association of family history of LC with risk of SPLC on top of high risk for SPLC in non-familial patients. The risks differed by sex, histology and type of affected relative. The data on family history of LC should alert about surveillance for SPLC and may be used in future risk stratification when eligibility for population screening is considered.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a adenocarcinoma
|2 Other
650 _ 7 |a incidence trend
|2 Other
650 _ 7 |a proband
|2 Other
650 _ 7 |a sibling risk
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Lung Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Lung Neoplasms: genetics
|2 MeSH
650 _ 2 |a Lung Neoplasms: pathology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Sweden: epidemiology
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Neoplasms, Second Primary: epidemiology
|2 MeSH
650 _ 2 |a Neoplasms, Second Primary: genetics
|2 MeSH
650 _ 2 |a Registries
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Incidence
|2 MeSH
650 _ 2 |a Genetic Predisposition to Disease
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
700 1 _ |a Sundquist, Kristina
|b 1
700 1 _ |a Sundquist, Jan
|b 2
700 1 _ |a Försti, Asta
|0 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
|b 3
|u dkfz
700 1 _ |a Hemminki, Akseli
|0 0000-0001-7103-8530
|b 4
700 1 _ |a Hemminki, Kari
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.1002/cam4.71431
|g Vol. 14, no. 23, p. e71431
|0 PERI:(DE-600)2659751-2
|n 23
|p e71431
|t Cancer medicine
|v 14
|y 2025
|x 2045-7634
909 C O |o oai:inrepo02.dkfz.de:306672
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER MED-US : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:04:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:04:21Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-08-08T17:04:21Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-08-08T17:04:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-07
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21